ドラッグデリバリーデバイスの世界市場：現状分析と予測（2022年～2028年）

世界のドラッグデリバリーデバイスの市場規模は、予測期間中に約6％のCAGRで成長すると予測されています。糖尿病患者の増加、がんや呼吸器疾患の有病率の増加、生物製剤の増加、ドラッグデリバリー関連の技術進歩は、市場の成長を促進しています。

当レポートでは、世界のドラッグデリバリーデバイス市場について調査しており、市場の洞察、市場動向、競合シナリオ、企業概要など、包括的な情報を提供しています。

目次

第1章 市場イントロダクション

• 市場の定義
• 主な目標
• ステークホルダー
• 制限

第2章 調査手法または仮定

• ドラッグデリバリーデバイス市場の調査プロセス
• ドラッグデリバリーデバイス市場の調査手法
• 回答者プロファイル

第3章 市場要約

第4章 エグゼクティブサマリー

第5章 ドラッグデリバリーデバイス市場に対するCOVID-19の影響

第6章 ドラッグデリバリーデバイス市場の収益（10億米ドル）（2020年～2028年）

第7章 市場の洞察：タイプ別

• 注射
• 吸入器
• その他

第8章 市場の洞察：技術別

• Bluetooth
• NFC
• その他

第9章 市場の洞察：用途別

• 腫瘍
• 感染症
• 呼吸器疾患
• 糖尿病
• その他

第10章 市場の洞察：地域別

• 北米
  • 米国
  • カナダ
  • その他の北米
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他のアジア太平洋地域
• 世界のその他の地域

第11章 ドラッグデリバリーデバイスの市場力学

• 市場促進要因
• 市場の課題
• 影響分析

第12章 ドラッグデリバリーデバイスの市場機会

第13章 ドラッグデリバリーデバイスの市場動向

第14章 需要側と供給側の分析

• 需要側分析
• 供給側分析

第15章 バリューチェーン分析

第16章 競合シナリオ

• 競合情勢
  • ポーターのファイブフォース分析

第17章 企業概要

• Pfizer Inc.
• Johnson & Johnson Services, Inc.
• F. Hoffmann-La Roche Ltd
• Novartis AG
• BD
• Bayer AG
• uniQure NV.
• SIBIONO
• GSK plc.
• Amgen Inc.

第18章 免責事項

Drug delivery devices are specialized tools made for a specific route of drug or therapeutic material administration. The devices are used once or more during medical procedures. Drug delivery devices present unique challenges in many areas of product development, such as regulatory strategy, design, and material considerations, as well as the creation and use of testing protocols. When providing pharmacological compounds that have therapeutic benefits in humans or animals, drug delivery devices are a crucial component. Growth in the number of diabetic patients as well as an increase in the prevalence of cancer and respiratory ailments are driving an increase in the use of drug delivery systems among patients and professionals. Moreover, in March 2021 researchers from Stanford University and the University of North Carolina at Chapel Hill (UNC) created a 3D-printed vaccine patch that they claim offers superior protection to a conventional vaccine shot. The creation of such innovative items is encouraging the use of medicine delivery products and fosters market expansion.

The Drug Delivery Devices Market is expected to grow at a steady rate of around 6% owing to the rising incidence of chronic and acute diseases, rising growth of biologics, rising technological advancements related to drug delivery devices, rising number of diabetes patients, and rising prevalence of cancer patients. Moreover, a large number of products available in the drug delivery industry are further creating opportunities for the key market players. For instance, Coalesce Product Development Limited, a UK-based drug delivery device development business that Novartis Sandoz acquired, is creating a variety of inhalation devices. This comprises updated models of breath-actuated inhalers, pre-metered dry powder inhalers, and pressurized metered dose inhalers.

Based on type, the market is segmented into injectable devices, inhalation devices, and others. The injectable segment witnessed a substantial CAGR during the 2021 period owing to the increasing demand for injectable systems such as syringes for drug delivery. Furthermore, the entry of global players into emerging markets adds to the growth of the market. For instance, BD announced that it has received pandemic orders worldwide for needles and syringes, totaling 2 billion injection devices to support COVID-19 vaccination efforts. Such high demand for syringes and needles is expected to boost the segmental growth till the vaccination gets over.

On the basis of technology, the market is categorized into bluetooth, NFC, and others. Among these, the bluetooth segment captured a significant share of the market in 2020 owing to higher utilization of the technology in order to connect drug delivery devices to smartphones. Additionally, greater bluetooth technology compatibility with other drug delivery devices and simplicity of use are anticipated to fuel the bluetooth sub-segment growth over the course of the projection period.

Based on application, the drug delivery devices market has been classified into oncology, infectious diseases, respiratory diseases, diabetes, and others. The diabetes segment is to witness higher adoption of drug devices during the forecast period. This is mainly due to increasing cases of diabetes patients all across the world. For instance, 34.2 million Americans have diabetes in 2018, of whom 26.8 million had a diagnosis and 7.3 million had been underdiagnosed, according to the American Diabetes Association (ADA). The adoption of drug delivery devices in the field of diabetes is therefore anticipated to be influenced by the rising number of cases of diabetes that have been diagnosed.

For a better understanding of the market adoption of the drug delivery devices industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. The main reasons for this region's growth include the existence of important market participants, highly developed healthcare infrastructure and spending, and strategic partnerships. Along with this, it is predicted that throughout the forecast period, the prevalence of chronic diseases in the U.S. and a growing emphasis on preventative care will fuel market expansion in this region. According to the American Cancer Society's 2022 report, 1.9 million new cases of cancer are anticipated to be diagnosed in the United States in 2022, and cancer cases are further anticipated to rise in the nation. As a result, demand for drug-delivery devices for various therapeutics is anticipated to rise in the region due to the high mortality rate associated with the disease.

Some of the major players operating in the market include: Pfizer, Inc.; Johnson & Johnson Services, Inc.; F. Hoffmann-La Roche, Ltd.; Novartis AG; BD; Bayer AG; uniQure N.V.; SIBIONO; GSK plc.; Amgen Inc.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Drug Delivery Devices Market
• 2.2. Research Methodology of the Drug Delivery Devices Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE DRUG DELIVERY DEVICES MARKET

6 DRUG DELIVERY DEVICES MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY TYPE

• 7.1. Injectable Devices
• 7.2. Inhalation Devices
• 7.3. Others

8 MARKET INSIGHTS BY TECHNOLOGY

• 8.1. Bluetooth
• 8.2. NFC
• 8.3. Others

9 MARKET INSIGHTS BY APPLICATION

• 9.1. Oncology
• 9.2. Infectious Diseases
• 9.3. Respiratory Diseases
• 9.4. Diabetes
• 9.5. Others

10 MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. U.K.
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Rest of Asia-Pacific
• 10.4. Rest of World

11 DRUG DELIVERY DEVICES MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges
• 11.3. Impact Analysis

12 DRUG DELIVERY DEVICES MARKET OPPORTUNITIES

13 DRUG DELIVERY DEVICES MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

• 14.1. Demand Side Analysis
• 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 COMPETITIVE SCENARIO

• 16.1. Competitive Landscape
  • 16.1.1. Porters Fiver Forces Analysis

17 COMPANY PROFILED

• 17.1 Pfizer Inc.
• 17.2 Johnson & Johnson Services, Inc.
• 17.3 F. Hoffmann-La Roche Ltd
• 17.4 Novartis AG
• 17.5 BD
• 17.6 Bayer AG
• 17.7 uniQure NV.
• 17.8 SIBIONO
• 17.9 GSK plc.
• 17.1 Amgen Inc.

18 DISCLAIMER